The effects of a biological response modifier, OK-432, on tumor-induced alterations in the host metabolism.
The effects of multicytokine inducer, OK-432, on tumor-induced metabolic alterations were studied by assessing three key regulatory enzymes of gluconeogenesis, de novo fatty acid synthesis and the triglyceride clearance pathways. Two Klinish Einheit (KE) of OK-432 was subcutaneously injected on alternate days, for 10 days, into Fischer 344 rats with or without methylcholanthrene-induced sarcoma. At the time of sacrifice, the tumors accounted for approximately 23% of their total body weight. The injections of OK-432 did not affect the amount of food intake in either the tumor bearers or the controls. The tissue lipoprotein lipase activities in the epididymal fat pads of the tumor bearers were significantly decreased compared with the controls (P < 0.01). Phosphoenolpyruvate carboxykinase activity in the liver was significantly increased (P < 0.01), while malic enzyme activity tended to be decreased in the tumor bearers compared with the controls. However, there were no significant differences in those activities depending on the OK-432 injections, even though OK-432 induced tumor necrosis factor (TNF) and increased cytotoxic activities in the mesenteric lymph nodes as well as in the spleen. Thus, although the role of monokines in inducing cancer cachexia is not yet clearly understood, OK-432 was not able to revert the tumor-induced metabolic alterations which lead to tissue wasting and cancer cachexia.
Noguchi
Y
Y
First Department of Surgery, Yokohama City University School of Medicine, Japan.
Tsuburaya
A
A
Makino
T
T
Fukuzawa
K
K
Nomura
K
K
Yoshikawa
T
T
Matsumoto
A
A
Moriya
Y
Y
Masuda
K
K
D000818:Animals; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002100:Cachexia / Q000209:etiology / Q000517:prevention & control*; D005227:Fatty Acids / Q000378:metabolism; D005943:Gluconeogenesis / Q000187:drug effects*; D007155:Immunologic Factors / Q000494:pharmacology*; D008071:Lipoprotein Lipase / Q000187:drug effects / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008291:Malate Dehydrogenase / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000187:drug effects / Q000378:metabolism; D010844:Picibanil / Q000494:pharmacology*; D051381:Rats; D011916:Rats, Inbred F344; D012513:Sarcoma, Experimental / Q000378:metabolism* / Q000503:physiopathology; D014280:Triglycerides / Q000378:metabolism
D001786:Blood Glucose; D005227:Fatty Acids; D007155:Immunologic Factors; D014280:Triglycerides; D010844:Picibanil; D008291:Malate Dehydrogenase; D008071:Lipoprotein Lipase; D010729:Phosphoenolpyruvate Carboxykinase (GTP)